Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

1.19

Margin Of Safety %

Put/Call OI Ratio

0.3

EPS Next Q Diff

-0.07

EPS Last/This Y

-0.32

EPS This/Next Y

0.67

Price

1.14

Target Price

10.68

Analyst Recom

1

Performance Q

-50.43

Relative Volume

0.92

Beta

0.46

Ticker: PRQR



21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-03-21PRQR1.6450.120.002861
2025-03-24PRQR1.650.370.001144
2025-03-25PRQR1.610.370.001144
2025-03-26PRQR1.530.370.001144
2025-03-27PRQR1.440.370.001144
2025-03-28PRQR1.40.370.001144
2025-03-31PRQR1.340.31999.991099
2025-04-01PRQR1.290.31999.991099
2025-04-02PRQR1.370.31999.991099
2025-04-03PRQR1.270.320.001109
2025-04-04PRQR1.1850.320.671122
2025-04-07PRQR1.1850.310.711122
2025-04-08PRQR1.130.311.501126
2025-04-09PRQR1.20.311.501126
2025-04-10PRQR1.1350.311.201137
2025-04-11PRQR1.110.300.001147
2025-04-14PRQR1.180.300.001147
2025-04-15PRQR1.190.300.001167
2025-04-16PRQR1.140.30999.991167
2025-04-17PRQR1.150.30999.991167
2025-04-18PRQR1.140.30999.991167
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1



21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-03-21PRQR1.64-59.7- -0.67
2025-03-24PRQR1.65-59.7- -0.67
2025-03-25PRQR1.61-59.7- -0.67
2025-03-26PRQR1.52-59.7- -0.67
2025-03-27PRQR1.44-59.7- -0.67
2025-03-28PRQR1.40-59.7- -0.67
2025-03-31PRQR1.33-59.7- -0.67
2025-04-01PRQR1.29-59.7- -0.67
2025-04-02PRQR1.37-59.7- -0.67
2025-04-03PRQR1.27-59.7- -0.67
2025-04-04PRQR1.18-59.7- -0.67
2025-04-07PRQR1.18-59.7- -0.67
2025-04-08PRQR1.13-59.7- -0.67
2025-04-09PRQR1.21-59.7- -0.67
2025-04-10PRQR1.13-59.7- -0.67
2025-04-11PRQR1.11-59.7- -0.67
2025-04-14PRQR1.18-59.7- -0.67
2025-04-15PRQR1.19-59.7- -0.67
2025-04-16PRQR1.15-59.7- -0.67
2025-04-17PRQR1.14-59.7- -0.67
2025-04-18PRQR1.14-59.7- -0.67
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1



21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-03-21PRQR0.0031.141.28
2025-03-24PRQR0.0031.141.28
2025-03-25PRQR0.0031.141.28
2025-03-26PRQR0.0031.141.45
2025-03-27PRQR0.0031.141.45
2025-03-28PRQR0.0031.141.45
2025-03-31PRQR0.0031.141.45
2025-04-01PRQR0.0031.141.45
2025-04-02PRQR0.0031.141.45
2025-04-03PRQR0.0031.141.45
2025-04-04PRQR0.0031.141.45
2025-04-07PRQR0.0031.141.45
2025-04-08PRQR0.0031.141.45
2025-04-09PRQR0.0031.141.45
2025-04-10PRQR0.0031.141.19
2025-04-11PRQR0.0031.141.19
2025-04-14PRQR0.0031.141.19
2025-04-15PRQR0.0031.141.19
2025-04-16PRQR0.0031.141.19
2025-04-17PRQR0.0031.141.19
2025-04-18PRQR0.0031.141.19
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

-0.1

Avg. EPS Est. Current Quarter

-0.16

Avg. EPS Est. Next Quarter

-0.17

Insider Transactions

Institutional Transactions

31.14

Beta

0.46

Average Sales Estimate Current Quarter

4

Average Sales Estimate Next Quarter

4

Fair Value

Quality Score

29

Growth Score

30

Sentiment Score

76

Actual DrawDown %

88

Max Drawdown 5-Year %

-93.9

Target Price

10.68

P/E

Forward P/E

PEG

P/S

5.87

P/B

1.28

P/Free Cash Flow

EPS

-0.35

Average EPS Est. Cur. Y​

-0.67

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-147.03

Relative Volume

0.92

Return on Equity vs Sector %

-51.3

Return on Equity vs Industry %

-37.9

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.12

EBIT Estimation

ProQR Therapeutics N.V.
Sector: Healthcare
Industry: Biotechnology
Employees: 166
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH) targeting patatin-like phospholipase domain-containing protein 3 (PNPLA3); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as additional programs in Rett Syndrome, additional CNS programs, and multiple other unnamed targets and programs. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
stock quote shares PRQR – ProQR Therapeutics N.V. Stock Price stock today
news today PRQR – ProQR Therapeutics N.V. stock forecast ,stock prediction 2023 2024 2025
marketwatch PRQR – ProQR Therapeutics N.V. yahoo finance google finance
stock history PRQR – ProQR Therapeutics N.V. invest stock market
stock prices PRQR premarket after hours
ticker PRQR fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Facebook-f Twitter Tiktok Instagram Youtube

Get Started

About